At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 16 enrolled
Drug / intervention
Vorinostat +1 moredrug
Likely dose
Vorinostat 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MK0683 Phase1 Clinical Study - Solid Tumor -
In Brief
A Phase 1 clinical trial evaluating Vorinostat for Tumors. Completed, enrolled 16 participants.
Detailed Summary
This is a clinical study to evaluate the safety and pharmacokinetics of an overseas determined maximum tolerated dose (MTD) of MK-0683 (vorinostat) in a Japanese patient population with solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTumors
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2006
First PostedSep 2006
Primary CompletionOct 2007
TodayJul 2026
First PostedSep 8, 2006
Enrollment StartJul 1, 2006
Primary CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.8 years ago
Interventions
Vorinostatdrug
600 mg daily (300 mg twice daily \[b.i.d.\]) for 3 consecutive days followed by 4 days of rest.
Vorinostatdrug
400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.